To characterise the outcomes of neoadjuvant chemotherapy (NAC) pre-treated patients found to be lymph node (LN)-positive at the time of radical cystectomy and pelvic lymph node dissection (RC/PLND) for urothelial carcinoma of the bladder (UCB).
Introduction
Recurrence rates for patients with lymph node (LN)-positive bladder cancer after radical cystectomy (RC) and bilateral pelvic lymph node dissection (PLND) are high. Only onethird of LN-positive patients will survive 3 years after RC/ PLND [1, 2] , with the majority of recurrences occurring within 2 years. Up to 25% of patients undergoing RC/PLND for muscle-invasive bladder cancer (MIBC) will have LN metastases identified on final pathological review [3] [4] [5] [6] .
Rates of utilisation of neoadjuvant chemotherapy (NAC) in patients with MIBC (cT2-4N0M0) have gradually increased following reports demonstrating survival benefit [7] [8] [9] [10] .
While the implementation of NAC has improved outcomes for patients with MIBC as a whole, outcomes for clinically non-metastatic patients treated with NAC who are found to be LN-positive at RC/PLND are not well studied. Prior publications have reported upon the outcomes of LN-positive patients undergoing induction chemotherapy followed by consolidative surgery [11] or have grouped clinically LNnegative patients (who receive true NAC) together with clinically LN-positive patients (who receive definitive or induction chemotherapy) [12] .
We hypothesised that patients treated with NAC found to have LN-positive disease after RC/PLND may have a significantly worse outcome compared to chemotherapy-na€ ıve LN-positive patients. The purpose of the present study was to characterise the outcomes of NAC pre-treated, pathological LN-positive patients managed with RC/PLND.
Patients and Methods

Study population
After Institutional Review Board approval, we queried our prospective institutional bladder cancer database. We identified 1484 consecutive patients who underwent RC between 2000 and 2010 for urothelial carcinoma of the bladder (UCB), of whom 306 (21%) were found to have LN metastasis on histopathological analysis. Of these patients, 198 were treated with curative intent RC/PLND for muscleinvasive UCB and had preoperative axial imaging demonstrating clinically LN-negative, non-metastatic (cN0M0) disease. The clinical staging of cN0M0 patients was initially determined by the treating physician and was verified by the investigators.
Perioperative systemic chemotherapy consisted primarily of cisplatin-based regimens, either gemcitabine/cisplatin (gemcitabine 1000 mg/m 2 and cisplatin 70 mg/m 2 on day 1, gemcitabine 1000 mg/m 2 on day 8) in a 21-day cycle; or methotrexate, vinblastine, adriamycin, and cisplatin (MVAC). Chemotherapy in patients who were clinically non-metastatic (cN0M0) before RC was classified as NAC, adjuvant chemotherapy (AC, administered within 3 months of RC/ PLND with no evidence of disease after RC/PLND), and salvage chemotherapy (chemotherapy delivered for recurrent disease after RC/PLND). All patients with clinically positive LNs before RC were excluded as they constituted a group of regionally metastatic patients and therefore received definitive preoperative chemotherapy (not NAC) if eligible.
In all, 43 of these patients (22%) were treated with NAC, 67 (34%) were treated with AC, and 93 (47%) did not receive any perioperative chemotherapy. Given their advanced age and significant additional comorbidities (P < 0.01) compared to patients who received chemotherapy, patients who did not receive any perioperative systemic chemotherapy were excluded from further analyses (Table S1) [13] . We further excluded five patients who received both NAC and AC, 13 who had a delay to initiation of AC (>3 months), and six patients who did not have 3-month follow-up. Our final comparative study cohorts consisted of 81 LN-positive patients treated with either NAC (n = 32) or AC (n = 49).
Surgical specimens were evaluated according to our standard institutional protocol. LNs were processed by a standard method that included dissection from the adipose tissue under bright light. No fat-clearing solutions were used. All identified LNs were sectioned and pathologically evaluated. Tumour stage was assigned according to the 2002 TNM American Joint Committee on Cancer classification [14] .
Follow-up was performed according to institutional protocols, which included interval evaluations for clinical and radiographic evidence of disease. Disease recurrence was defined as any radiographic or pathologically verified documentation of disease. Cause of death was prospectively entered into the institutional database, verified by chart review, and corroborated by death certificates.
Statistical analysis
Associations between categorical clinicopathological variables were examined using Fisher's exact test. Survival probabilities were estimated using Kaplan-Meier methods. Univariate and multivariable Cox proportional hazards models were used to estimate the risks of disease recurrence and cancer-specific mortality (CSM) after RC/PLND. Multivariable models adjusted for pathological T-stage (≤pT2, pT3, pT4) and LN density.
Given the timing of NAC and AC relative to RC/PLND, a potential bias against NAC secondary to time lag from diagnosis to surgery was accounted for by using a previously published methodology as a sensitivity analysis [15] . Recurrence and CSM were assessed as dichotomous variables up to 2 years after RC. Patients censored before 2 years were excluded, leaving 77 patients for each model. The same predictors were then used to build univariate and multivariable logistic regression models for the dichotomous outcomes. All reported P values are two-sided, and statistical significance was set as P < 0.05. Analyses were conducted using Stata 12.0 (Stata Corp., College Station, TX, USA).
Results
The median (interquartile range [IQR]) age of our cohort at time of RC was 64 (57-71) years. The median (IQR) number of positive LNs was 2 (1-5), with a median (IQR) number of LNs removed of 20 (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . These clinicopathological characteristics were similar in the NAC and AC groups. LNpositive patients treated with NAC had more advanced primary tumour stage than LN-positive patients treated with AC (P = 0.02) and were more often female (50% vs 24%, P = 0.03) ( Table 1 ). The median (IQR) follow-up time for survivors was 7.3 (5.0-9.5) years. In all, 46 patients had disease recurrence.
Most patients received platinum-based chemotherapy, representing 29 of 32 (91%) of patients treated with NAC, and 40 of 49 (82%) of patients treated with AC. Most patients treated with NAC received at least three cycles of platinum-based chemotherapy (72%), with 27 (84%) receiving at least two cycles. Similarly, 37 (76%) and 40 (82%) patients treated with AC received at least three and two cycles of platinum-based chemotherapy, respectively. Our univariate Cox models showed that clinically nonmetastatic patients treated with NAC who were found to be LN-positive at RC were at a significantly higher risk of disease recurrence (hazard ratio [HR] 2.86, 95% CI 1.58-5.19; P = 0.001) and CSM (HR 2.50, 95% CI 1.34-4.65; P = 0.004) as compared to LN-positive patients treated with AC ( Fig. 1 and Table 2 ; Fig. S1 shows overall survival data). After adjusting for pathological stage and LN density in our multivariable models, LN-positive patients previously treated with NAC were still at greater risk of disease recurrence and CSM (HR 3.11, 95% CI 1.59-6.07, P = 0.001 and HR 3.05, 95% CI 1.46-6.35, P = 0.003, respectively).
Given the relative timing of NAC, RC, and AC, we performed a 2-year outcomes logistic regression sensitivity analysis to eliminate any potential bias against LN-positive patients treated with NAC ('delay' to RC). The results of the sensitivity analysis confirmed the above findings, that LNpositive patients after NAC were at higher risk of disease recurrence (odds ratio [OR] 5.29, 95% CI 1.89-14.83, P = 0.002) and CSM (OR 4.28, 95% CI 1.59-11.50, P = 0.004) than LN-positive patients treated with AC (Table 3) . Again, these results remained significant after adjustment for pathological stage and LN density in multivariable analyses (OR 5.59, 95% CI 1.95-16.01, P = 0.001 and OR 5.24, 95% CI 1.78-15.46, P = 0.003, respectively).
Discussion
We found that patients with clinically non-metastatic MIBC treated with NAC and found to be LN-positive at RC/PLND had significantly worse outcomes as compared to chemotherapy-na€ ıve LN-positive patients subsequently treated with AC. LN-positive NAC patients had a 3-year recurrencefree survival (RFS) estimate of 26%, as compared with 60% for LN-positive AC patients. By comparison, a 36% 3-year RFS was found in a historical series of 1550 LN-positive patients treated with RC/PLND alone [1] .
While NAC has improved outcomes for patients with MIBC, not all patients will harbour chemotherapy-sensitive disease. Most patients with significant residual disease after NAC will ultimately experience disease recurrence [8] . In our present study, patients treated with NAC and found to have LNpositive disease represent an empirically defined chemotherapy-resistant cohort. Conversely, within a group of chemotherapy-na€ ıve LN-positive patients, there exists a proportion with chemotherapy-sensitive disease that will benefit from AC. Therefore, it is not unexpected that chemotherapy non-response is associated with worse cancerspecific outcomes. In a study of 52 patients with bladder cancer and pathologically-confirmed LN metastases, response to preoperative platinum-based chemotherapy was associated with improved survival, and LN status was more important than local tumour status [16] .
Our present finding that LN-positive patients previously treated with NAC have extremely poor outcomes are significant and have not previously been well described. Most studies investigating prognostic factors in patients with LNpositive bladder cancer exclude patients treated with either NAC or AC [2, 4, 17, 18] . While some studies have reported on the outcomes of LN-positive patients after preoperative chemotherapy, most either focus upon clinically LN-positive patients [11] or group clinically LN-negative patients (who receive true NAC) and clinically LN-positive patients (who receive full-course induction chemotherapy) together [12] . Retrospective studies including patients treated in an earlier era often do not have strict criteria for preoperative axial imaging. Further, although studies have identified that pathological responders to NAC have better outcomes than non-responders, the comparison of NAC non-responders with chemotherapy-na€ ıve non-responders has not been well characterised [19] . Another study reported on the incidence of LN metastases in clinically non-metastatic patients ACCI, age-adjusted Charlson Comorbidity Index; NOS, not otherwise specified.
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By demonstrating the poor survival of LN-positive NAC patients, we provide supportive information that this characteristic be used in the stratification of LN-positive patients that are studied in clinical trials. Expected outcomes, power calculations and perhaps altered response patterns to study drugs may better be interpreted by recognising the differential outcomes of the different LN-positive patient populations. Additionally, the poor observed outcomes provide strong rationale for enrolling LN-positive NAC patients in prospective clinical trials utilising novel therapeutic agents or approaches to chemotherapy. Some examples of relevant ongoing clinical trials include those of adjuvant atezolizumab (ClinicalTrials.gov NCT02450331) and another examining adjuvant nivolumab (ClinicalTrials.gov NCT02632409) with high-risk features after RC. Both of these trials include both patients without prior treatment and also patients who received NAC.
Genomic profiling of bladder cancer holds the promise to rationally define subsets of patients who might benefit from targeted therapies [21] . However, there are numerous challenges to this approach, as studies have begun to identify the scope of the genomic heterogeneity of UCB [22, 23] and intra-tumour heterogeneity [24] , and initial trials of rational targeted therapy for metastatic bladder cancer have had disappointing results [25] . Another strategy involves the elucidation of molecular or genetic predictors of chemosensitivity. While studies have identified potential prognostic or predictive biomarkers of response to chemotherapy in bladder cancer and other malignancies, results have been mixed [26, 27] .
The magnitude of the effects identified by our present study should be interpreted with caution, as five patients who recurred before initiation of AC were excluded from the AC group, as they were classified as having received salvage chemotherapy rather than AC. The drastic difference in survival between these two treatment groups may not be quite as large if these patients were included. However, whilst the AC LN-positive patients may have had slightly worse outcomes in an 'intention-to-treat' analysis, they are comparable to those reported in the literature [12] . Furthermore, the outcomes for LN-positive NAC patients are poor even with respect to historical series of LN-positive patients not treated with AC.
Our present study has several limitations, including those common to all retrospective analyses. Our sample size was limited by the inclusion/exclusion criteria we used to obtain comparable cohorts on LN-positive patients in terms of demographics and clinical disease staging. Nevertheless, there was a large effect size. Although we only included patients with muscle-invasive and clinically non-metastatic disease (cT2-4N0M0) confirmed by our institution's pathologists and radiologists, we did not perform a re-review of histology and axial imaging. Finally, as the patients in our present study were treated by various oncologists and surgeons over a 10-year period, our data are heterogeneous and representative of practice at a large academic cancer centre.
In summary, we found that patients with clinically LNnegative non-metastatic (cN0M0) MIBC treated with NAC and found to have LN-positive disease at time of RC/PLND have poor outcomes, with a 3-year RFS estimate of 26%. These outcomes were significantly poorer than those for chemotherapy-na€ ıve cN0M0 patients found to have LNpositive disease and subsequently treated with AC.
